We’ve seen this before on Gilead pre-pandemic;
It traded sideways above this zone for a little over a year on descending YOY earnings since 2016. Following the gap down 19 AUG, we’re now seeing a bullish MACD divergence plus an ascending RSI on the daily to signal a break of the recent down trend. With more positive news surrounding their COVID-19 treatment drug, Remdesivir, would love to see a short term build up before ER to the 67-70 zone.
ER date has not been announced but is estimated to be on 10/22.
It traded sideways above this zone for a little over a year on descending YOY earnings since 2016. Following the gap down 19 AUG, we’re now seeing a bullish MACD divergence plus an ascending RSI on the daily to signal a break of the recent down trend. With more positive news surrounding their COVID-19 treatment drug, Remdesivir, would love to see a short term build up before ER to the 67-70 zone.
ER date has not been announced but is estimated to be on 10/22.
Ordem cancelada:
Could see further dip into this weekly demand zone before a rebound. I am pretty confident in the demand zone though and would not expect it to dip beyond it, even with negative Remdesivir news, at least not any time soon. However, I will not be trading this name.